electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026
electroCore (ECOR) will report its third-quarter financial results after the market closes on November 4, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
electroCore (ECOR) will report its third-quarter financial results after the market closes on November 4, 2026. The results cover the quarter ended September 30, 2026. Management will host a conference call and webcast at 4:30 PM EST that day to review results and answer questions. A webcast replay will be available in the Investors section of the company’s website.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKAWAY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial results for the third quarter ended September 30, 2026, after the market closes on Wednesday, November 4, 2026. Management will host a conference call and webcast at 4:30 PM EST that day to review the results and answer questions.
Participants may join by telephone or webcast using the details below.
Wednesday, November 4, 2026 at 4:30 pm EST
Participant Dial-In: 877-407-8835 / +1 201-689-8779
Conference ID #: 13763480
Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=af6qsd3k
A replay of the webcast will be available in the Investors section of the Company’s website at investor.electrocore.com.
About electroCore, Inc.
electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
